Pre-made Firivumab benchmark antibody ( Whole mAb, anti-Influenza A HA therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Firivumab biosimilar, Whole Mab: Anti-Influenza A HA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-214-1mg	1mg	3090
GMP-Bios-ab-214-10mg	10mg	Inquiry
GMP-Bios-ab-214-100mg	100mg	Inquiry
GMP-Bios-ab-214-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

For more than 100mg, click here for inquiry. >>

Description

Products Name (INN Index)	Pre-Made Firivumab biosimilar, Whole Mab: Anti-Influenza A HA therapeutic antibody
INN Name	Firivumab
Target	Influenza A HA
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Preclinical
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2014
Year Recommended	2015
Companies	Celltrion
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Influenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections
Development Tech	na

GENEMEDI: 6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China; Email: [email protected] [email protected]; Telephone: +86-21-50478399 Fax: 86-21-50478399; Privacy Policy